Other highlights in the June 21 JNCIStudy Links High Cadmium Levels with Breast Cancer
High levels of cadmium may be tied to an increased risk of breast cancer, according to a new study. However, whether increased cadmium actually causes breast cancer or whether cadmium levels increase in response to treatment or the disease itself remains unknown.
Cadmium is a long-lasting heavy metal that accumulates in the body. It is found in food and tobacco smoke and is thought to be a carcinogen. Jane A. McElroy, Ph.D., of the University of Wisconsin in Madison, and colleagues examined cadmium levels in urine samples of 246 breast cancer patients between ages 20 and 69 and 254 matched controls.
The authors found that women with the highest cadmium levels had twice the breast cancer risk of those with the lowest cadmium levels. They write, "Given the ubiquitous exposure of the general population to cadmium, the mode of the association between cadmium exposure and breast cancer risk warrants further study."
Contact: Linda Dietrich, University of Wisconsin, 608-263-6585, [email protected]
Drug from Milk Thistle Prevents Lung Cancer in a Mouse Model
Silibinin, a compound from the milk thistle, inhibits lung tumor blood vessel formation in mice and may help prevent the growth and development of lung tumors, a study reports.
Rajesh Agarwal, Ph.D., of the University of Colorado Health Sciences Center in Denver, and colleagues tested the effect of dietary silibinin on mice injected with a chemical that causes lung cancer. Mice given silibinin had lower numbers of lung tumors than mice given a diet lacking silibinin, and their tumors had a lower size and blood vessel count. The authors conclude that dietary silibinin should be investigated as a cancer preventing agent for lung cancer in humans.
Contact:Kenna Bruner, [email protected]
Tolfenamic Acid Works Against Compounds that Cause Pancreatic Cancer
Tolfenamic acid, a non-steroidal anti-inflammatory drug (NSAID), fights pancreatic cancer by reducing the levels of some cellular proteins that contribute to tumor growth and metastasis. Stephen Safe, Ph.D., of Texas A&M University in College Station, and colleagues at the M.D. Anderson Cancer Center in Houston, Tx., used a mouse model of pancreatic cancer to investigate the anticancer activities of tolfenamic acid and related compounds.
Contact: Stephen Safe, 979-845-5988, [email protected]
KGF and FGFR2b Are Players in Cancer and Cancer Therapy
Keratinocyte growth factor (KGF) is used to limit epithelial tissue damage from radiation and chemotherapy in patients with blood cancers. However, concerns arise over whether KGF's use in patients with epithelial tumors could lead to tumor growth or protect the tumor cells from the killing effect of radiation and chemotherapy.
A review by Paul W. Finch, Ph.D., of Croton-on-Hudson in New York and Jeffrey S. Rubin, M.D., Ph.D., of the National Cancer Institute in Bethesda, Md., suggests KGF and its receptor (FGFR2b) typically do not stimulate the formation and growth of tumors. Rather, research suggests that in some situations expression of FGFR2b may induce cell death. The authors review KGF and FGFR2b's involvement in various cancers.
Contact: NCI Press Officers, 301-496-6641, [email protected]
Also in the June 21 JNCI:
- Impact of Classification of Hilar Cholangiocarcinomas (Klatskin Tumors) on the Incidence of Intra- and Extrahepatic Cholangiocarcinoma in the United States
- Urologist Plays Key Role in Determining Use of Hormone Therapy in Prostate Cancer: http://www.eurekalert.org/emb_releases/2006-06/jotn-upk061506.php
- Study Identifies New Tumor Suppressor: http://www.eurekalert.org/emb_releases/2006-06/jotn-si061506.php
Note: The Journal of the National Cancer Institute is published by Oxford University Press and is not affiliated with the National Cancer Institute. Attribution to the Journal of the National Cancer Institute is requested in all news coverage. Visit the Journal online at http://jncicancerspectrum.oxfordjournals.org/.
Published on PsychCentral.com. All rights reserved.